Serum Institute, Codagenix initiate Ph 1 dosing of COVI-VAC vaccine
Serum Institute, Codagenix initiate Ph 1 dosing of COVI-VAC vaccine
12 January 2021 | News Phase 1 trial will evaluate a total of 48 volunteers at multiple dose levels to determine the safety and tolerability COVI-VAC
Source credit: Shutterstock
US based Codagenix Inc and the Serum Institute of India Pvt Ltd (SII) have announced that the first patient has been dosed in the Phase 1 clinical trial of COVI-VAC, a single-dose, intranasal, live attenuated vaccine against SARS-CoV-2, the virus that causes COVID-19.
Designed as a randomised, double-blinded, placebo-controlled dose-escalation study, the Phase 1 trial will evaluate a total of 48 volunteers at multiple dose levels to determine the safety and tolerability COVI-VAC. In addition, the study will evaluate the vaccine s ability to provoke an immune response – measuring neutralising antibodies, mucosal immunity in the airway and cellular immunit
Covishield FAQ: Serum Institute answers all your queries ahead of COVID-19 vaccination drill
Representational Image
Ahead of the nationwide inoculation exercise against coronavirus disease (COVID-19) across India, the Serum Institute has issued a fact-sheet to answer all the Frequently Asked Questions (FAQs) that vaccine beneficiaries might have in preparation of the drill.
As with any other necessary fact-sheets of the sort, it contains information to help you understand the risks and benefits of the vaccine, which most citizens are set to receive soon as the long-promised cure against the disease caused by SARS-CoV-2.
The Covishield vaccines have already reached some states. Till 4 PM, about 54,72,000 doses were received by the states and Union Territories, the Union Ministry of Health and Family Welfare had said earlier on this day. By January 14, 100 per cent doses will be received.
Highlights
Union Health Minister said, It is a matter of great pride for us that the pharma major developed the first indigenous vaccine
Pneumonia is the single largest infectious cause of death among children under five years of age worldwide Pneumosil has been extensively evaluated in 5 randomised controlled clinical trials and has demonstrated comparable safety, he added
New Delhi: Union Health Minister Dr Harsh Vardhan inaugurated India’s first pneumococcal conjugate vaccine, “Pneumosil”, which has been developed by the Serum Institute of India. The vaccine would help in preventing about 67,800 child mortality under 5 years of age in India from pneumococcal diseases every year.
Synopsis
PNEUMOSIL has been developed through a collaboration spanning over a decade among Serum Institute of India Pvt Ltd, PATH and Bill and Melinda Gates Foundation. This significant milestone is aimed at improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low-and middle-income countries.
Reuters
PUNE: Serum Institute of India, the largest vaccine manufacturer in the world by doses, announces the launch of India s first indigenously developed pneumococcal vaccine - PNEUMOSIL.
It was launched in the presence of Dr. Harsh Vardhan, Minister of Health and Family Welfare on Monday.
PNEUMOSIL has been developed through a collaboration spanning over a decade among Serum Institute of India Pvt Ltd, PATH and Bill and Melinda Gates Foundation. This significant milestone is aimed at improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low-and middle-income countries, read a press statement.